A Protocol for the Inclusion of Minoritized Persons in Alzheimer Disease Research From the ADNI3 Diversity Taskforce
Creators
- Okonkwo, Ozioma C.1
- Rivera Mindt, Monica2
- Ashford, Miriam T.3
- Conti, Catherine3
- Strong, Joe1
- Raman, Rema4
- Donohue, Michael C.4
- Nosheny, Rachel L.5
- Flenniken, Derek3
- Miller, Melanie J.3
- Diaz, Adam3
- Soto, Annabelle M.6
- Ances, Beau M.7
- Beigi, Maryam R.8
- Doraiswamy, P. Murali9
- Duara, Ranjan10
- Farlow, Martin R.11
- Grossman, Hillel T.12
- Mintzer, Jacobo E.13
- Reist, Christopher14
- Rogalski, Emily J.15
- 1. University of Wisconsin
- 2. Fordham University
- 3. Department of Veterans Affairs Medical Center
- 4. University of Southern California
- 5. San Francisco Veteran's Administration Medical Center
- 6. Icahn School of Medicine at Mount Sinai
- 7. Washington University in Saint Louis
- 8. University of California, Los Angeles
- 9. Duke University
- 10. Mount Sinai Medical Center
- 11. Indiana University Health
- 12. Mount Sinai School of Medicine
- 13. Medical University of South Carolina
- 14. MindX Sciences Inc.
- 15. University of Chicago
Description
Importance: Black or African American (hereinafter, Black) and Hispanic or Latino/a/x (hereinafter, Latinx) adults are disproportionally affected by Alzheimer disease, but most research studies do not enroll adequate numbers of both of these populations. The Alzheimer's Disease Neuroimaging Initiative-3 (ADNI3) launched a diversity taskforce to pilot a multipronged effort to increase the study inclusion of Black and Latinx older adults.
Objective: To describe and evaluate the culturally informed and community-engaged inclusion efforts to increase the screening and enrollment of Black and Latinx older adults in ADNI3.
Design, Setting, and Participants: This cross-sectional study used baseline data from a longitudinal, multisite, observational study conducted from January 15, 2021, to July 12, 2022, with no follow-up. The study was conducted at 13 ADNI3 sites in the US. Participants included individuals aged 55 to 90 years without cognitive impairment and those with mild cognitive impairment or Alzheimer disease.
Exposures: Efforts included (1) launch of an external advisory board, (2) changes to the study protocol, (3) updates to the digital prescreener, (4) selection and deployment of 13 community-engaged research study sites, (5) development and deployment of local and centralized outreach efforts, and (6) development of a community-science partnership board.
Main Outcomes and Measures: Screening and enrollment numbers from centralized and local outreach efforts, digital advertisement metrics, and digital prescreener completion.
Results: A total of 91 participants enrolled in the trial via centralized and local outreach efforts, of which 22 (24.2%) identified as Latinx and 55 (60.4%) identified as Black (median [IQR] age, 65.6 [IQR, 61.5-72.5] years; 62 women [68.1%]). This represented a 267.6% increase in the monthly rate of enrollment (before: 1.11 per month; during: 4.08 per month) of underrepresented populations. For the centralized effort, social media advertisements were run between June 1, 2021, and July 31, 2022, which resulted in 2079 completed digital prescreeners, of which 1289 met criteria for subsequent site-level screening. Local efforts were run between June 1, 2021, to July 31, 2022. A total of 151 participants underwent site-level screening (100 from local efforts, 41 from centralized efforts, 10 from other sources).
Conclusions and Relevance: In this cross-sectional study of pilot inclusion efforts, a culturally informed, community-engaged approach increased the inclusion of Black and Latinx participants in an Alzheimer disease cohort study.
Notes
Data availability
See Supplement 2.Files
okonkwo_2024_oi_240838_1722613151.62307.pdf
Files
(1.6 MB)
| Name | Size | Download all |
|---|---|---|
|
Article md5:1eec8b085ba5f188c527c4d55c0a435b |
1.2 MB | Preview Download |
|
Supplemental files md5:9703b20a86a3322cb9e02ead5effcdc6 |
429.2 kB | Preview Download |
Additional details
Identifiers
- DOI
- 10.1001/jamanetworkopen.2024.27073
- Other
- oai:uchicago.tind.io:13373
Funding
- National Institute on Aging
- U19AG024904
- National Institutes of Health
- Alzheimer’s Disease Neuroimaging Initiative
- Department of Defense
- W81XWH-12-2-0012
- National Institute of Biomedical Imaging and Bioengineering
- AbbVie
- Alzheimer's Association
- Alzheimer's Drug Discovery Foundation
- Araclon Biotech
- BioClinica Inc
- Biogen
- Bristol-Myers Squibb Co
- CereSpir Inc
- Cogstate
- Eisai Inc
- Elan Pharmaceuticals Inc
- Eli Lilly and Co
- EuroImmun
- F. Hoffmann-La Roche Ltd
- Genentech Inc
- Fujirebio
- GE Healthcare
- IXICO Ltd
- Janssen Alzheimer Immunotherapy Research & Development LLC
- Johnson & Johnson Pharmaceutical Research & Development LLC
- Lumosity
- Lundbeck
- Merck & Co Inc
- Meso Scale Diagnostics LLC
- NeuroRx Research
- Neurotrack Technologies
- Novartis Pharmaceuticals Corp
- Pfizer Inc
- Piramal Imaging
- Servier
- Takeda Pharmaceutical Co
- Transition Therapeutics
- Canadian Institutes of Health Research